LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

LLY

753.95

+2.28%↑

JNJ

151.07

+1.12%↑

UNH

291.93

+7.04%↑

ABBV

183.3

+0.85%↑

NVO

64.06

-2.9%↓

Search

ImmunityBio Inc

Open

BrancheGesundheitswesen

2.83 6.79

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

2.62

Max

2.9

Schlüsselkennzahlen

By Trading Economics

Einkommen

-70M

-130M

Verkäufe

9M

17M

EPS

-0.15

Gewinnspanne

-785.046

Angestellte

680

EBITDA

-24M

-64M

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+144.18% upside

Dividenden

By Dow Jones

Nächstes Ergebnis

8. Aug. 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-324M

2.1B

Vorheriger Eröffnungskurs

-3.96

Vorheriger Schlusskurs

2.83

Nachrichtenstimmung

By Acuity

50%

50%

173 / 382 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Strong Bearish Evidence

ImmunityBio Inc Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

5. Mai 2025, 17:20 UTC

Wichtige Markttreiber

ImmunityBio Slides Following FDA Refusal-to-File Letter

5. Mai 2025, 11:38 UTC

Wichtige Markttreiber

ImmunityBio Requests Meeting With FDA Over Rejected Bladder Treatment Application

29. Jan. 2025, 15:59 UTC

Wichtige Markttreiber

ImmunityBio Shares Rise After Collaboration, Supply Agreement With BeiGene

24. Okt. 2024, 13:50 UTC

Akquisitionen, Fusionen, Übernahmen

This Biotech Stock Could Rocket 800%, Analyst Says -- Barrons.com

Peer-Vergleich

Kursveränderung

ImmunityBio Inc Prognose

Kursziel

By TipRanks

144.18% Vorteil

12-Monats-Prognose

Durchschnitt 6.08 USD  144.18%

Hoch 8 USD

Tief 4.25 USD

Basierend auf 3 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für ImmunityBio Inc – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

3 ratings

2

Buy

1

Halten

0

Sell

Technischer Score

By Trading Central

2 / 2.63Unterstützung & Widerstand

Kurzfristig

Strong Bearish Evidence

Mittelfristig

Weak Bearish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

173 / 382 Ranking in Gesundheitswesen

Nachrichtenstimmung

Neutral

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Durchschnitt

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über ImmunityBio Inc

ImmunityBio, Inc., a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies. The company's platforms have generated therapeutic agents that are currently being or planned to be studied in clinical trials across various indications in liquid and solid tumors, including bladder, lung and colorectal cancers, and glioblastoma multiforme. Its lead biologic product candidate is Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors. The company has collaboration agreements with National Cancer Institute. It also has license agreements with 3M Innovative Properties Company; Access to Advanced Health Institute; LadRx Corporation; Sanford Health; Shenzhen Beike Biotechnology Co. Ltd.; Viracta Therapeutics, Inc.; and GlobeImmune, Inc. The company is based in San Diego, California.